Retinol binding protein 4 promotes hyperinsulinism‑induced proliferation of rat aortic smooth muscle cells

Li,Fei; Xia,Ke; Sheikh,Md Sayed  Ali; Cheng,Jinfang; Li,Chuanchang; Yang,Tianlun

doi:10.3892/mmr.2014.2028

Retinol binding protein 4 promotes hyperinsulinism‑induced proliferation of rat aortic smooth muscle cells

Authors:
- Fei Li
- Ke Xia
- Md Sayed Ali Sheikh
- Jinfang Cheng
- Chuanchang Li
- Tianlun Yang
View Affiliations

Affiliations: Department of Cardiology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: March 7, 2014 https://doi.org/10.3892/mmr.2014.2028
Pages: 1634-1640
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have suggested that retinol binding protein 4 (RBP4), an adipocytokine related to insulin resistance (IR), may play an important role in the development of atherosclerosis and cardiovascular diseases (CVD). Abnormal proliferation and migration of vascular smooth muscle cells (VSMCs) is one of the most common causes of atherosclerosis. Hyperinsulinism promotes proliferation of VSMCs through the MAPK pathway. However, whether RBP4 is involved in insulin-induced proliferation of VSMCs leading to atherosclerosis remains unclear. In the present study, we evaluated the role of RBP4 and the potential relevance of signaling pathways in this process. Different concentrations of RBP4 (1 and 4 µg/ml) were added to rat aortic smooth muscle cells (RASMCs) during insulin-induced proliferation. The levels of cell growth signaling pathway proteins ERK1/2, p-ERK1/2, JAK2, p-JAK2, STAT3 and p-STAT3 were assessed by western blotting in order to identify the pathway(s) that are activated during insulin-induced proliferation. The specific inhibitors of ERK1/2 (PD98059) and JAK2 (AG490) were used to confirm our findings. Insulin induced proliferation of RASMCs in a concentration- and time-dependent manner, and increased the expression of ERK1/2, p-ERK1/2, JAK2, p-JAK2, STAT3 and p-STAT3 in a time-dependent manner. RBP4 enhanced insulin-induced proliferation of RASMCs and expression of p-ERK1/2 and p-JAK2. RBP4‑induced proliferation of RASMCs was reduced by the ERK1/2 inhibitor, while it was unaffected by the JAK2 inhibitor. These results suggest that RBP4 mediates VSMC proliferation induced by insulin via activation of the MAPK pathway, and highlight RBP4 as a modulator of atherosclerosis in hyperinsulinemia, therby enhancing our understanding on a number of unexpected aspects of CVD.

View Figures

View References

1	Al-Harithy RN and Al-Ghamdi S: Serum resistin, adiposity and insulin resistance in Saudi women with type 2 diabetes mellitus. Ann Saudi Med. 25:283–287. 2005.PubMed/NCBI
2	Bauche IB, Ait El Mkadem S, Rezsohazy R, Funahashi T, Maeda N, Miranda LM and Brichard SM: Adiponectin downregulates its own production and the expression of its AdipoR2 receptor in transgenic mice. Biochem Biophys Res Commun. 345:1414–1424. 2006. View Article : Google Scholar : PubMed/NCBI
3	Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L and Kahn BB: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 436:356–362. 2005. View Article : Google Scholar : PubMed/NCBI
4	Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson P, Smith U and Kahn BB: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 354:2552–2563. 2006. View Article : Google Scholar : PubMed/NCBI
5	Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Schleicher E, Fritsche A and Häring HU: High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care. 30:1173–1178. 2007. View Article : Google Scholar : PubMed/NCBI
6	Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK and Park KS: Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care. 29:2457–2461. 2006. View Article : Google Scholar
7	Ribel-Madsen R, Friedrichsen M, Vaag A and Poulsen P: Retinol-binding protein 4 in twins: regulatory mechanisms and impact of circulating and tissue expression levels on insulin secretion and action. Diabetes. 58:54–60. 2009. View Article : Google Scholar : PubMed/NCBI
8	Klöting N, Graham TE, Berndt J, Kralisch S, Kovacs P, Wason CJ, Fasshauer M, Schön MR, Stumvoll M, Blüher M and Kahn BB: Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 6:79–87. 2007.PubMed/NCBI
9	Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S and Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 334:952–957. 1996. View Article : Google Scholar : PubMed/NCBI
10	Pepe MG, Ginzton NH, Lee PD, Hintz RL and Greenberg PL: Receptor binding and mitogenic effects of insulin and insulin-like growth factors I and II for human myeloid leukemic cells. J Cell Physiol. 133:219–227. 1987. View Article : Google Scholar : PubMed/NCBI
11	Faries PL, Rohan DI, Wyers MC, Marin ML, Hollier LH, Quist WC and LoGerfo FW: Vascular smooth muscle cells derived from atherosclerotic human arteries exhibit greater adhesion, migration, and proliferation than venous cells. J Surg Res. 104:22–28. 2002. View Article : Google Scholar : PubMed/NCBI
12	Mahmoudi MJ, Mahmoudi M, Siassi F, Hedayat M, Pasalar P, Chamari M, Abolhassani H, Rezaei N and Saboor-Yaraghi AA: Circulating retinol-binding protein 4 concentrations in patients with coronary artery disease and patients with type 2 diabetes mellitus. Int J Diabetes Dev Ctries. 32:105–110. 2012. View Article : Google Scholar
13	Mallat Z, Simon T, Benessiano J, Clement K, Taleb S, Wareham NJ, Luben R, Khaw KT, Tedgui A and Boekholdt SM: Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women. J Clin Endocrinol Metab. 94:255–260. 2009. View Article : Google Scholar : PubMed/NCBI
14	Matsumoto K, Miyake S, Yano M, Ueki Y, Yamaguchi Y, Akazawa S and Tominaga Y: Insulin resistance and arteriosclerosis obliterans in patients with NIDDM. Diabetes Care. 20:1738–1743. 1997. View Article : Google Scholar : PubMed/NCBI
15	Giannattasio C and Mancia G: Arterial distensibility in humans: modulating mechanisms, alterations in diseases and effects of treatment. J Hypertens. 20:1889–1899. 2002. View Article : Google Scholar : PubMed/NCBI
16	Page C and Doubell AF: Mitogen-activated protein kinase (MAPK) in cardiac tissues. Mol Cell Biochem. 157:49–57. 1996. View Article : Google Scholar : PubMed/NCBI
17	Pessin JE and Saltiel AR: Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest. 106:165–169. 2000. View Article : Google Scholar : PubMed/NCBI
18	Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR and Mandarino LJ: Insulin resistance differentially affects the PI3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 105:311–320. 2000. View Article : Google Scholar : PubMed/NCBI
19	Horvath CM: STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci. 25:496–502. 2000. View Article : Google Scholar : PubMed/NCBI
20	Watanabe S, Mu W, Kahn A, Jing N, Li JH, Lan HY, Nakagawa T, Ohashi R and Johnson RJ: Role of JAK/STAT pathway in IL-6-induced activation of vascular smooth muscle cells. Am J Nephrol. 24:387–392. 2004. View Article : Google Scholar : PubMed/NCBI
21	Guo F, Zarella C and Wagner WD: STAT4 and the proliferation of artery smooth muscle cells in atherosclerosis. Exp Mol Pathol. 81:15–22. 2006. View Article : Google Scholar : PubMed/NCBI
22	Ost A, Danielsson A, Liden M, Eriksson U, Nystrom FH and Stralfors P: Retinol-binding protein-4 attenuates insulin-induced phosphorylation of IRS1 and ERK1/2 in primary human adipocytes. FASEB J. 21:3696–3704. 2007. View Article : Google Scholar : PubMed/NCBI
23	Takebayashi K, Sohma R, Aso Y and Inukai T: Effects of retinol binding protein-4 on vascular endothelial cells. Biochem Biophys Res Commun. 408:58–64. 2011. View Article : Google Scholar : PubMed/NCBI
24	Wang CC, Gurevich I and Draznin B: Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes. 52:2562–2569. 2003. View Article : Google Scholar : PubMed/NCBI
25	Ingelsson E, Sundström J, Melhus H, Michaëlsson K, Berne C, Vasan RS, Risérus U, Blomhoff R, Lind L and Ärnlöv J: Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Atherosclerosis. 206:239–244. 2009. View Article : Google Scholar : PubMed/NCBI
26	Bobbert T, Raila J, Schwarz F, Mai K, Henze A, Pfeiffer AF, Schweigert FJ and Spranger J: Relation between retinol, retinol-binding protein 4, transthyretin and carotid intima media thickness. Atherosclerosis. 213:549–551. 2010. View Article : Google Scholar : PubMed/NCBI
27	Wu J, Shi YH, Niu DM, Li HQ, Zhang CN and Wang JJ: Association among retinol-binding protein 4, small dense LDL cholesterol and oxidized LDL levels in dyslipidemia subjects. Clin Biochem. 45:619–622. 2012. View Article : Google Scholar : PubMed/NCBI
28	von Eynatten M, Lepper PM, Liu D, Lang K, Baumann M, Nawroth PP, Bierhaus A, Dugi KA, Heemann U, Allolio B and Humpert PM: Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia. 50:1930–1937. 2007.
29	Cabré A, Lázaro I, Girona J, Manzanares J, Marimón F, Plana N, Heras M and Masana L: Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. J Intern Med. 262:496–503. 2007.PubMed/NCBI
30	Neeli I, Liu ZM, Dronadula N, Ma ZA and Rao GN: An essential role of the Jak-2/STAT-3/cytosolic phospholipase A(2) axis in platelet-derived growth factor BB-induced vascular smooth muscle cell motility. J Biol Chem. 279:46122–46128. 2004. View Article : Google Scholar : PubMed/NCBI
31	Sahar S, Dwarakanath RS, Reddy MA, Lanting L, Todorov I and Natarajan R: Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis. Circ Res. 96:1064–1071. 2005. View Article : Google Scholar : PubMed/NCBI